Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_927_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contributors
- •Acknowledgments
- •Contents
- •Inferior Mesenteric Artery
- •Collateral Circulation
- •VENOUS DRAINAGE
- •Superior Mesenteric Vein
- •Inferior Mesenteric Vein
- •LYMPHATIC DRAINAGE
- •INNERVATION
- •COLON AND RECTUM PHYSIOLOGY
- •Colonic Physiology
- •Absorption and Secretion
- •Digestion
- •Propulsion and Storage
- •ANAL CANAL ANATOMY
- •Lining
- •Muscles of the Anorectal Region
- •Perineal Body
- •Pelvic Floor Muscles
- •Innervation of the Anus
- •Motor Innervation
- •Sensory Innervation
- •Arterial Supply of the Anus
- •Lymphatic Drainage of the Anus
- •Venous Drainage of the Anus
- •ANAL CANAL PHYSIOLOGY
- •Mechanisms of Continence
- •Defecation
- •Physiologic Testing
- •Anal Manometry
- •Defecography by Fluoroscopy or Magnetic Resonance Imaging
- •Balloon Expulsion Test
- •Colon
- •Saline Continence Test
- •Rectal Compliance
- •Electromyography
- •Nerve Stimulation Techniques
- •Course and Peritoneal Coverings
- •Rectum
- •Peritoneal Relations and Fascial Attachments
- •ARTERIAL SUPPLY
- •Superior Mesenteric Artery
- •Suggested Reading
- •EXTERNAL HEMORRHOIDS
- •CLINICAL EVALUATION
- •NONEXCISIONAL OPTIONS
- •Medical Management
- •Sclerotherapy
- •Energy-Based Destruction
- •Hemorrhoidal Ligation with Rubber Bands
- •EXCISIONAL HEMORRHOIDECTOMY
- •Instrumentation for Excisional Hemmorrhoidectomy
- •PROCEDURE FOR PROLAPSING HEMORRHOIDS (STAPLED HEMMORHOIDOPEXY)
- •DOPPLER-GUIDED HEMORRHOIDAL DEARTERIALIZATION
- •POSTOPERATIVE MANAGEMENT AFTER HEMORRHOID SURGERY
- •CONCLUSION
- •Suggested Reading
- •INTRODUCTION
- •DIAGNOSIS
- •PATHOPHYSIOLOGY
- •High-Pressure Chronic Anal Fissure
- •Low- and Normal-Pressure Chronic Anal Fissure
- •MANAGEMENT
- •Topical Creams
- •Botulinum Toxin
- •Fissurectomy
- •Cutaneous Advancement Flap
- •Lateral Internal Sphincterotomy
- •Surgical Technique
- •Risk of Incontinence
- •Tailored Sphincterotomy
- •SUMMARY: CHOICE OF TREATMENT
- •Suggested Reading
- •CLASSIFICATION
- •PRESENTATION
- •DIAGNOSIS AND EVALUATION
- •Preparation and Examination
- •TREATMENT
- •INTERSPHINCTERIC ANAL FISTULA
- •Clinical Findings
- •TREATMENT
- •Incontinence Risk
- •TRANSSPHINCTERIC ANAL FISTULA
- •Clinical Findings
- •Treatment
- •Cutting Seton
- •Sphincter-Preserving Techniques
- •LIFT
- •ADVANCEMENT FLAP
- •PARTIAL FISTULOTOMY
- •SUPRASPHINCTERIC ANAL FISTULA
- •Fistula Plugs
- •EXTRASPHINCTERIC ANAL FISTULA
- •SPECIAL SITUATIONS
- •Crohn Disease
- •Deep Postanal Space Abscess with a Horseshoe Fistula
- •SUMMARY
- •Suggested Reading
- •DEFINITION
- •CAUSES
- •HISTORY AND PHYSICAL EXAMINATION
- •SURGICAL ANATOMY
- •ETIOLOGY
- •NATURAL HISTORY OF THE DISEASE AND SPREAD PATHWAYS
- •CLINICAL FEATURES
- •Perianal Abscess
- •Ischiorectal Abscess
- •Intersphincteric Abscess
- •Supralevator Abscess
- •Deep Postanal Abscess
- •Submucosal Abscess
- •DIAGNOSIS
- •Treatment of Anorectal Abscesses
- •Large Abscesses
- •Searching for a Fistula
- •Ischiorectal Abscess
- •Intersphincteric Abscesses
- •Supralevator Abscess
- •Submucosal Abscess
- •Role of Antibiotics and Biopsy
- •Postoperative Care
- •Complications
- •RECURRENCE AND THE DEVELOPMENT OF FISTULA IN ANO
- •Suggested Reading
- •INTRODUCTION
- •ETIOLOGY
- •TREATMENT OPTIONS
- •Medical
- •Nonsurgical Closure
- •Fistula Plug
- •Fibrin Glue
- •Surgical Closure
- •Anal Approach
- •Rectal Advancement Flap
- •Advancement Sleeve Flap
- •Turnbull-Cutait Anastomosis
- •Transvaginal Approach
- •Perineal Approach
- •Ligation of the Intersphincteric Fistula Tract
- •Episioproctotomy
- •Tissue Interposition
- •SPECIAL CONSIDERATIONS
- •Use of a Stoma
- •Postoperative Care
- •Sexual Function/Vaginal Dryness
- •Recurrence
- •CONCLUSION
- •Suggested Reading
- •ETIOLOGY
- •PRESENTATION
- •TREATMENT
- •Asymptomatic Pilonidal Sinus
- •Pilonidal Abscess
- •Chronic Pilonidal Sinus
- •NONOPERATIVE MANAGEMENT
- •Hair Removal
- •SURGERY
- •Lateral Drainage, Curettage, and Midline Pit Excision
- •Local Excision and Healing by Secondary Intention
- •FLAP-BASED PROCEDURES
- •Karydakis Procedure
- •Cleft Lift Procedure
- •Rhomboid Excision and Flap Repair
- •Cavity Drainage
- •CONCLUSION
- •Suggested Reading
- •ETIOLOGY
- •CLINICAL PRESENTATION AND EVALUATION
- •ANTIBIOTIC TREATMENT
- •NONANTIBIOTIC TREATMENT
- •SURGICAL TREATMENT
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •ETIOLOGY
- •PRIMARY CAUSES OF PRURITUS ANI
- •Pathophysiology
- •HISTORY
- •EXAMINATION
- •TREATMENT
- •SECONDARY PRURITUS ANI TREATMENT
- •Anorectal Conditions
- •Infections
- •Dermatologic Conditions
- •Neoplastic Causes
- •Systemic Disease
- •REFRACTORY OR PERSISTENT PRURITUS ANI
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •DEFINITION
- •CLASSIFICATION OF ANAL STENOSIS
- •Cause
- •Spasm
- •Postoperative Scarring
- •Stenosis Due to Chronic Diarrhea
- •Age-Related Stenosis
- •SYMPTOMS
- •Examination Findings
- •PREVENTION OF POSTOPERATIVE ANAL STENOSIS
- •TREATMENT
- •Nonoperative Management
- •Anal Dilation
- •Surgical Management
- •Anoplasty
- •Postoperative Complications of Anoplasty
- •Suggested Reading
- •BACKGROUND AND EPIDEMIOLOGY
- •PRESENTATION OF DISEASE AND DIAGNOSIS
- •TREATMENT OF ANAL CONDYLOMA
- •Medical Therapies
- •Trichloracetic and Bichloracetic Acid
- •Imiquimod
- •Other Medical Treatments
- •Ablative Therapies
- •Cryotherapy
- •Surgical Excision/Fulguration
- •Laser
- •Recurrent Disease
- •Treatment Algorithm
- •CONCLUSION
- •Suggested Reading
- •BACTERIAL INFECTIONS
- •Gonorrhea
- •Preferred Clinical Approach
- •Chlamydia trachomatis and Lymphogranuloma venereum
- •Preferred Clinical Approach
- •Chancroid
- •Preferred Clinical Approach
- •Granuloma Inguinale
- •Preferred Clinical Approach
- •Syphilis (“The Great Masquerader”)
- •Preferred Clinical Approach
- •VIRAL INFECTIONS
- •Herpes Simplex Virus
- •Preferred Clinical Approach
- •Condylomata Acuminata
- •Clinical Manifestations
- •Treatment
- •Preferred Clinical Approach
- •Electrocautery
- •OTHER DISORDERS
- •Suggested Reading
- •INTRODUCTION
- •HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (FORMERLY BOWEN DISEASE)
- •Management
- •PERIANAL PAGET DISEASE
- •Management
- •Suggested Reading
- •INTRODUCTION
- •EPIDEMIOLOGY AND RISK FACTORS
- •PATHOPHYSIOLOGY
- •CLINICAL PRESENTATION AND DIAGNOSIS
- •SURGERY
- •Management of the Primary Tumor
- •Management of Lymph Nodes
- •SURVIVAL
- •BASAL CELL CANCER OF THE PERIANAL REGION
- •Suggested Reading
- •INTRODUCTION
- •ANATOMIC CONSIDERATIONS
- •EPIDEMIOLOGY
- •SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL
- •Surveillance
- •Local Excision
- •Inguinal Lymph Node Management
- •Extrapelvic Metastases
- •PERIANAL SQUAMOUS CELL CARCINOMA
- •ANAL CANCER AND HIV INFECTION
- •Suggested Reading
- •A GENERAL APPROACH
- •CHRONIC PROCTALGIA
- •LEVATOR ANI SYNDROME
- •Diagnosis
- •Treatment
- •PROCTALGIA FUGAX
- •COCCYGODYNIA
- •CONCLUSION
- •Selected Readings
- •DESCRIPTION OF DEFECTS
- •Perineal Fistula
- •Rectal Atresia
- •Vestibular Fistula
- •Imperforate Anus without Fistula
- •Rectourethral Bulbar Fistula
- •Rectourethral Prostatic Fistula
- •Cloaca
- •Recto-Bladder-Neck Fistula
- •NEONATAL MANAGEMENT
- •Anoplasty
- •Management of Functional Sequelae
- •ETIOLOGY, PATHOPHYSIOLOGY, AND INCIDENCE
- •DIAGNOSIS
- •Anorectal Manometry
- •Rectal Biopsy
- •Resuscitation
- •Main Repair
- •Duhamel Procedure
- •Soave Procedure
- •Dehiscence and Retraction
- •Constipation
- •ASSESSMENT
- •Medical Management
- •Postanal Repair
- •Anal Encirclement
- •Muscle Transposition
- •Continence Enemas
- •Stem Cells, Bulking Agents, and Other Techniques
- •Fecal Diversion
- •CONCLUSIONS
- •DEFINITION
- •ETIOLOGY
- •BENIGN RECTAL STRICTURES
- •Medical Treatment
- •Digital Evacuation
- •Enemas and Colonic Lavage
- •Oral Solutions
- •Stool Softeners
- •Laxatives
- •Endoscopic Disimpaction
- •SURGERY
- •Acute
- •PREVENTION
- •CONCLUSION
- •PATHOPHYSIOLOGY
- •Recommendations
- •Nonoperative Management
- •CONCLUSIONS
- •DEFINITION
- •DIAGNOSIS
- •Transanal Repairs
- •Transvaginal Repairs
- •EPIDEMIOLOGY
- •Location of the Foreign Body
- •Intraperitoneal or Extraperitoneal
- •Tailgut Cysts
- •Duplication Cysts
- •Transanal Excision
- •Anterior Resection
- •Physical Examination
- •Locoregional Evaluation
- •Nodal Staging
- •Extramural Venous Invasion
- •Locoregional Imaging Synoptic Reports
- •Distant Metastatic Evaluation
- •RADIATION-RELATED TOXICITIES
- •Boosting the Dose
- •HIGH-DOSE-RATE ENDORECTAL BRACHYTHERAPY
- •Total Mesorectal Excision
- •Ligation of the Inferior Mesenteric Artery
- •Distal Resection Margins
- •Drainage
- •Positioning and Equipment
- •Trocar Placement
- •Exposure of the Operating Field
- •Division of the Vessels and Splenic Flexure Mobilization
- •Mobilization and Division of the Rectum
- •Exteriorization of the Specimen
- •Creation of the Anastomosis
- •Abdominoperineal Resection
- •Closure of the Anal Opening
- •Mobilization of the Rectum
- •Proximal Division of the Left Colon
- •Perineal Dissection and Exteriorization
- •Closure of Pelvic Wound and Trocar Incisions and Creation of the Colostomy
- •INITIAL SELECTION
- •Patient Preparation
- •Transanal Excision
- •MANAGEMENT OF THE SPECIMEN
- •Salvage Resection after Local Excision
- •Axial Recurrences
- •Anterior Recurrences
- •Posterior Recurrences
- •Lateral Recurrences
- •THERAPY
- •Patient Selection
- •Procedures
- •Complications
- •PREVENTION
- •SUMMARY
- •RISK ASSESSMENT
- •PREOPERATIVE PULMONARY ASSESSMENT AND MANAGEMENT
- •MANAGEMENT OF PATIENTS RECEIVING ANTITHROMBOTIC THERAPY
- •Diagnosis
- •Diet
- •5-Aminosalycilic Acid
- •Mild to Moderate Ulcerative Colitis
- •Proctitis and Left-Sided Ulcerative Colitis
- •Left-Sided Disease
- •Extensive Disease
- •Lack of Response to 5-Aminosalycilic Acid
- •Oral Budesonide
- •Corticosteroids
- •Severe Ulcerative Colitis
- •Cyclosporine
- •Azathioprine and 6-Mercaptopurine
- •Biologic Agents
- •Adalimumab
- •Golimumab
- •How to Choose an Anti-TNF-α Agent
- •Complications
- •What to Do Before Starting Anti-TNF-α Therapy
- •What to Do Once Treatment with an Anti-TNF-α Agent Is Started
- •Antiadhesion Molecules
- •Alternative Therapies
- •Nicotine
- •Clinical Scenarios
- •Quiescent Disease
- •Fulminant or Toxic Colitis
- •Flexible Sigmoidoscopy with Biopsies
- •Deep Vein Thrombosis Prophylaxis
- •Evaluate for Tuberculosis and Hepatitis B
- •Avoid Narcotics and Antidiarrheal Medications
- •Do Not Use Antibiotics
- •Diet as Tolerated
- •Perform Close Observation and Consult Colorectal Surgery upon Admission
- •Vaccinations
- •Pregnancy
- •Cancer Risk
- •Drug-Induced Colitis
- •Proctectomy Surgical Technique
- •Staging the Procedure
- •Technique of Creation of an Ileoanal J Pouch
- •Problems with Reach of the Pouch
- •Complications after Ileal Pouch–Anal Anastomosis
- •Overall Quality of Life
- •Function of the Pouch
- •Pouchitis
- •Pouch Failure
- •Salvage of the Failed Pelvic Pouch
- •PRESENTATION
- •EVALUATION
- •Surgical Options
- •CONCLUSION
- •Pelvis Sepsis and Anastomotic Leak
- •Postoperative Bleeding from the Pouch
- •Pouch-Perineal and Pouch-Vaginal Fistulae
- •Outlet Dysfunction
- •POUCHITIS
- •Genetic Factors
- •CONCLUSIONS
- •Late Complications
- •Valve Slippage
- •Parastomal Hernia
- •Crohn Disease
- •Pouchitis
- •Valve Stenosis
- •Pouch Excision
- •CONCLUSIONS
- •Crohn Disease
- •Radiation
- •PREVENTION
- •Reconstruction of the Perineum with a Flap
- •5-Aminosalicylates
- •Antibiotics
- •Biologic Agents
- •SMOKING
- •NUTRITION
- •Disease of the Colon and Rectum
- •SPECIAL SITUATIONS
- •Medications
- •Abscess
- •Fistula
- •Neoplasia
- •OUTCOME
- •Anal Sepsis
- •Stenosis
- •CONCLUSION
- •CONCLUSION
- •CYTOMEGALOVIRUS COLITIS
- •KAPOSI SARCOMA
- •COMPLICATED DIVERTICULITIS
- •INTRODUCTION
- •ETIOLOGY
- •Right-Sided Obstruction
- •Left-Sided Obstruction
- •Self-Expanding Metallic Stents
- •COLONIC VOLVULUS
- •Signs and Symptoms
- •Diagnostic Imaging
- •Signs and Symptoms
- •Diagnostic Imaging
- •TRANSVERSE COLON VOLVULUS
- •Pathophysiology
- •Diagnostic Imaging
- •Signs and Symptoms
- •Treatment
- •EPIDEMIOLOGY
- •ETIOLOGY
- •Initial Management
- •Pharmacologic Management
- •BIOLOGY
- •MARGIN
- •NODES
- •COMORBIDITIES
- •SUMMARY
- •SCREENING FOR COLORECTAL CANCER
- •Flexible Sigmoidoscopy
- •Stool DNA
- •Surveillance Colonoscopy after Endoscopic Resection of a Malignant Polyp
- •Surveillance Colonoscopy in Patients with Colorectal Cancer
- •Surveillance Colonoscopy in Patients with a Family History of Colorectal Cancer or Adenomatous Polyps
- •CONCLUSION
- •INTRODUCTION
- •GROWTH CONTROL
- •DNA REPAIR
- •COMPLEXITY
- •REGISTRIES
- •DEFINITIONS
- •Genotype/Phenotype
- •Surgical Options for the Large Bowel
- •Extracolonic Manifestations
- •Hepatoblastoma
- •Surveillance
- •The IRA
- •The IPAA
- •Oligopolyposis/Attenuated Familial Adenomatous Polyposis
- •PTEN Tumor Hamartoma Syndrome
- •INTRODUCTION
- •BIOLOGY
- •EPIDEMIOLOGY
- •GENETICS AND DESMOID RISK
- •DESMOID SEVERITY: A STAGING SYSTEM
- •MANAGEMENT
- •Setting Expectations
- •A Philosophy of Care
- •Extra-abdominal Desmoid Tumors
- •Abdominal Wall Tumors
- •Intra-abdominal Desmoid Disease
- •Workup
- •Medical Treatment
- •Role of Surgery
- •Complications of Desmoid Disease
- •Small Bowel Obstruction
- •Ureteric Obstruction
- •Abscess/Enterocutaneous Fistula
- •Superior Mesenteric Artery Aneurysm
- •Points about Operating on Persons with Desmoid Disease
- •SUMMARY AND GENERAL COMMENTS ABOUT THE EFFECT OF DESMOID DISEASE ON SURGICAL STRATEGY IN FAMILIAL ADENOMATOUS POLYPOSIS
- •Suggested Reading
- •INTRODUCTION
- •HISTORICAL PERSPECTIVE AND CLARIFICATION OF TERMS
- •GENETIC AND MOLECULAR CAUSE OF LYNCH SYNDROME
- •HISTOLOGIC FEATURES OF LYNCH TUMORS
- •DIAGNOSING LYNCH SYNDROME
- •Clinical Criteria
- •Models
- •Tumor Testing
- •GENETIC COUNSELING AND TESTING
- •CLINICAL MANIFESTATIONS AND MANAGEMENT
- •COLORECTAL CANCER RISK MANAGEMENT
- •Surveillance Colonoscopy and Polypectomy
- •Chemoprevention
- •Surgery
- •Colectomy in the Absence of Cancer
- •Treatment of Colon Cancer
- •Rectal Cancer in Persons with Lynch Syndrome
- •RISK MANAGEMENT OF EXTRACOLONIC MANIFESTIONS
- •Endometrial and Ovarian Cancer
- •Upper Gastrointestinal Tract
- •Urinary Tract
- •Skin Neoplasms
- •Other Cancers
- •CLINICAL VARIATIONS OF HNPCC AND LYNCH SYNDROME
- •Familial Colorectal Cancer Type X
- •Tumor Lynch
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •PATHOLOGY OF APPENDICEAL MALIGNANT TUMORS
- •Carcinoid Tumors
- •Epithelial (Noncarcinoid) Tumors of the Appendix
- •Mucinous Adenoma and Adenocarcinoma
- •Nonmucinous Adenocarcinoma
- •DIAGNOSIS OF APPENDICEAL MALIGNANT TUMORS
- •Carcinoid
- •Adenocarcinoma and Mucinous Adenocarcinoma
- •Pseudomyxoma Peritonei Syndrome
- •Carcinoid Tumors
- •Appendiceal Adenocarcinoma
- •Management of Appendiceal Neoplasms with Peritoneal Dissemination
- •Perioperative Chemotherapy
- •Serial Debulking
- •CYTOREDUCTIVE SURGERY AND PERIOPERATIVE CHEMOTHERAPY
- •Survival by Completeness of Cytoreduction
- •Survival by Histologic Assessment
- •Survival by Prior Surgical Score
- •Morbidity and Mortality Rates
- •Peritonectomy
- •Perioperative Chemotherapy
- •Suggested Reading
- •INTRODUCTION
- •EPIDEMIOLOGY
- •Prognostic Factors
- •PREOPERATIVE EVALUATION
- •PREOPERATIVE PREPARATION
- •OPERATIVE PRINCIPLES AND TECHNIQUES
- •Exploration
- •Surgical Treatment of Right Colon Cancer
- •Surgical Treatment of Transverse Colon Cancer
- •Surgical Treatment of Splenic Flexure and Descending Colon Cancer
- •Surgical Treatment of Sigmoid Colon Cancer
- •LAPAROSCOPIC COLECTOMY
- •SPECIAL CONSIDERATIONS
- •Obstruction and Perforation
- •Prophylactic Oophorectomy
- •POSTOPERATIVE SURVEILLANCE
- •SUMMARY
- •Suggested Readings
- •INTRODUCTION
- •CHEMOTHERAPY
- •5-Fu
- •Capecitabine
- •Irinotecan
- •Oxaliplatin
- •MAINTENANCE CHEMOTHERAPY
- •BIOLOGIC AGENTS
- •FIRST-LINE TARGETED OPTIONS
- •THIRD- AND FOURTH-LINE OPTIONS
- •OLIGOMETASTATIC DISEASE
- •ROLE OF RESECTION OF PRIMARY LESION
- •IMMUNOTHERAPY
- •CONCLUSIONS
- •Suggested Reading
- •INTRODUCTION
- •DIAGNOSIS AND PREOPERATIVE WORKUP
- •Imaging
- •Serologic and Molecular Markers
- •Histology
- •Needle Biopsy
- •Multidisciplinary Planning
- •STAGING AND PROGNOSIS
- •PROGNOSTIC SCORES
- •TREATMENT
- •Chemotherapy
- •Neoadjuvant Chemotherapy for Resectable Liver Disease
- •Neoadjuvant Chemotherapy for Unresectable Liver Disease
- •Adjuvant Chemotherapy
- •Hepatic Arterial Infusion
- •Resectability
- •Resectable Liver Disease
- •Synchronous Liver Metastasis
- •Unresectable Liver Disease
- •Repeat Resections for Multiple Liver Metastases
- •Local Ablative Therapy
- •Radiofrequency Ablation
- •Microwave Ablation
- •Cryotherapy
- •Irreversible Electroporation
- •Colorectal Liver Metastases with Extrahepatic Spread
- •Lung
- •Peritoneal
- •Lymph Node Involvement
- •Inferior Vena Cava
- •Recurrence
- •SURVEILLANCE
- •CONCLUSION
- •Suggested Readings
- •INTRODUCTION
- •INDICATIONS FOR RESECTION OF COLORECTAL METASTASES
- •OUTCOMES OF PATIENTS UNDERGOING RESECTION AND PROGNOSTIC FACTORS
- •LUNG AND LIVER METASTASIS
- •SURGICAL APPROACH
- •DEVELOPMENT OF A PROSPECTIVE RANDOMIZED TRIAL: THE PULMONARY METASTASECTOMY IN COLORECTAL CANCER TRIAL
- •CONCLUSION
- •Suggested Reading
- •INTRODUCTION
- •BENIGN NONADENOMATOUS LESIONS OF THE COLON AND RECTUM
- •Benign Lymphoid Hyperplasia
- •Lipomas
- •Treatment
- •CAVERNOUS HEMANGIOMA
- •Characteristic Features
- •Treatment
- •Surgery (Laparotomy/Laparoscopic)
- •LEIOMYOMA AND LEIOMYOSARCOMA
- •Characteristic Features
- •Surgery
- •PRIMARY LYMPHOMA OF THE COLON AND RECTUM
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •ETIOLOGY AND PATHOGENESIS
- •CLASSIFICATION
- •CLINICAL PRESENTATION
- •DIAGNOSIS
- •MANAGEMENT
- •OUTCOME
- •SPECIAL TOPICS
- •Ischemic Colitis after Aortic Surgery
- •Colonic Ischemia after Cardiopulmonary Bypass
- •Ischemic Colitis Associated with Colon Carcinoma and Obstructing Colon Lesions
- •Total Colonic Ischemia
- •Ischemic Proctosigmoiditis
- •CONCLUSION
- •Suggested Readings
- •INTRODUCTION
- •ETIOLOGY
- •DIAGNOSIS
- •Physical Examination
- •Imaging
- •Diagnostic Peritoneal Lavage
- •Laparoscopy
- •TREATMENT
- •Colon Injuries
- •Damage Control
- •Rectal Injuries
- •Overview
- •Diversion
- •Direct Repair
- •Drainage
- •Distal Washout
- •Rectal Foreign Bodies
- •Suggested Reading
- •INTRODUCTION
- •PAIN
- •INFERTILITY
- •DIAGNOSIS
- •Physical Examination
- •Endoscopy
- •Imaging
- •SURGICAL MANAGEMENT
- •Results after Surgical Therapy
- •Combined Medical and Surgical Therapy
- •CONCLUSION
- •Suggested Reading
- •INTRODUCTION
- •ETIOLOGY
- •CLASSIFICATION
- •HISTOLOGY AND GROSS PATHOLOGY
- •SYMPTOMS
- •DIAGNOSIS
- •TREATMENT
- •Suggested Readings
- •INTRODUCTION
- •CAUSES
- •CLASSIFYING CONSTIPATION
- •ASSESSMENT
- •History
- •Physical Examination
- •INVESTIGATIONS
- •TREATMENT
- •Medical
- •Newer Promotility Agents
- •Biofeedback for Pelvic Floor Dyssynergia
- •Change in Position of Defecation
- •Surgery
- •Outlet Obstruction Constipation
- •Suggested Reading
- •EXTENT OF THE PROBLEM
- •CLINICAL PRESENTATION
- •IMAGING
- •MRI and Ultrasound
- •MANAGEMENT OF SMALL BOWEL OBSTRUCTION
- •Nonadhesive Obstruction
- •Hernias
- •Crohn Disease
- •Malignancy
- •Intussusception
- •Gallstone Ileus
- •Bariatric Patient
- •Surgical Technique
- •Adhesive Obstruction
- •Hernias
- •Malignancy
- •Intussusception
- •Gallstone Ileus
- •The Bariatric Patient
- •Laparoscopic versus Open Lysis of Adhesions
- •Early Postoperative Bowel Obstruction
- •Prevention of Adhesions
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •DIETARY MANAGEMENT OF SHORT BOWEL SYNDROME
- •PHARMACOLOGIC TREATMENT OF SHORT BOWEL SYNDROME
- •PARENTERAL AND ENTERAL NUTRITION
- •HORMONAL TREATMENT FOR SHORT BOWEL SYNDROME
- •COMPLICATIONS ASSOCIATED WITH SHORT BOWEL SYNDROME
- •CONCLUSION
- •Suggested Reading
- •INTRODUCTION
- •GUT ADAPTATION
- •MEDICAL MANAGEMENT
- •SURGICAL REHABILITATION
- •Strategy
- •Autologous Reconstruction
- •Intestinal Lengthening
- •INTESTINAL AND MULTIVISCERAL TRANSPLANTATION
- •Types
- •Indications
- •Contraindications
- •Early Referral
- •Transplantation Surgery
- •Postoperative Management
- •Current Global Activities
- •Long-Term Survival
- •Allograft Function
- •Quality of Life
- •New Insights
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •CLINICAL PRESENTATION
- •INVESTIGATIONS IN UPPER GASTROINTESTINAL CROHN DISEASE
- •MEDICAL TREATMENT
- •ENDOSCOPIC TREATMENT
- •SURGERY
- •SUMMARY
- •Suggested Readings
- •INTRODUCTION
- •MEDICAL MANAGEMENT
- •INDICATIONS FOR SURGERY
- •PREOPERATIVE CONSIDERATIONS
- •OPERATIVE APPROACH
- •SURGICAL OPTIONS
- •Bypass
- •Resection
- •Strictureplasty
- •SPECIAL SITUATIONS
- •Medications
- •Abscess
- •Free Perforation
- •Hemorrhage
- •Growth Retardation
- •Fistula
- •Neoplasia
- •Obstruction
- •OUTCOME
- •SUMMARY
- •Selected Reading
- •INTRODUCTION
- •PRESENTATION
- •DIAGNOSIS
- •MANAGEMENT
- •Adenocarcinoma without Metastatic Disease
- •Carcinoid Tumors
- •Lymphomas
- •GIST Tumors
- •CONCLUSION
- •ACKNOWLEDGMENT
- •Suggested Readings
- •DEFINITION
- •INCIDENCE, EPIDEMIOLOGY, AND RESEARCH
- •CLINICAL PRESENTATION
- •DIAGNOSIS
- •CLASSIFICATION
- •SURGICAL TREATMENT
- •Small Intestine
- •Appendix
- •Colon
- •Rectum
- •Locally Advanced and Metastatic Disease
- •Hedinger Syndrome
- •ADJUVANT THERAPY
- •FOLLOW-UP
- •PROGNOSIS
- •Suggested Reading
- •INTRODUCTION
- •PATHOGENESIS
- •GENERAL ASPECTS OF CARE
- •COMPLICATIONS
- •PLAN OF CARE
- •Prevention
- •Stabilization
- •Wound Care
- •Nutritional Support
- •Nasogastric Tubes and Other Drainage Tubes
- •Protection of the Gastric, Duodenal, and Upper Gastrointestinal Tract Mucosa from Ulceration
- •Other Supplements
- •Investigation/Elucidation
- •Therapeutic Decisions
- •Will It Close?
- •The Decision to Operate
- •Timing of Surgery
- •Surgery
- •Choice of Incision
- •The Operation Itself
- •Anastomosis
- •Abdominal Wound Closure
- •What Type of Operation Should One Undertake?
- •Gastrostomy and Feeding Jejunostomy
- •The Healing Phase
- •Fibrin Glue
- •Short Bowel Syndrome
- •PROGNOSIS
- •Suggested Reading
- •INTRODUCTION
- •ACUTE MESENTERIC ISCHEMIA
- •Clinical Presentation
- •Evaluation
- •Treatment
- •SMA Embolus
- •SMA Thrombus
- •Mesenteric Venous Thrombosis
- •Nonocclusive Mesenteric Ischemia
- •Bowel Viability
- •Laparoscopy
- •CHRONIC MESENTERIC ISCHEMIA
- •Presentation
- •Evaluation
- •Operative Treatment
- •Angioplasty
- •CONCLUSION
- •Suggested Readings
- •BACKGROUND
- •PATHOPHYSIOLOGY
- •PREDISPOSING RISK FACTORS
- •GRADING SYSTEMS
- •DIAGNOSTIC WORKUP
- •PREVENTION
- •MANAGEMENT OF RADIATION ENTERITIS
- •Management of Radiation Injury to the Small Bowel
- •Acute Radiation Enteritis
- •Chronic Radiation Enteritis
- •Management of Radiation Injury to the Colon
- •Acute Radiation Colitis
- •Chronic Radiation Colitis
- •Management of Radiation Injury to the Rectum
- •Topical Therapy
- •Hyperbaric Oxygen
- •Medical Therapy
- •Endoscopic Management
- •Surgery
- •CONCLUSION
- •Suggested Readings
- •INTRODUCTION
- •IDENTIFICATION OF THE HIGH-RISK PATIENT
- •MINIMIZING RISK ASSOCIATED WITH EMERGENCY SURGERY
- •MINIMIZING RISK ASSOCIATED WITH CARDIAC DISEASE
- •MINIMIZING RISK ASSOCIATED WITH PULMONARY DISEASE
- •MINIMIZING RISK ASSOCIATED WITH IMMUNOSUPPRESSION
- •Steroids
- •Diabetes
- •Chemoradiotherapy
- •MINIMIZING RISK ASSOCIATED WITH MALNUTRITION
- •MINIMIZING RISK ASSOCIATED WITH HEPATIC DISEASE
- •MINIMIZING RISK ASSOCIATED WITH RENAL DISEASE
- •MINIMIZING RISK IN MORBIDLY OBESE PATIENTS
- •Suggested Reading
- •INTRODUCTION
- •ANATOMIC FACTORS
- •The Ureters
- •Presacral Veins
- •Pelvic Nerves
- •POSTOPERATIVE CHANGES IN THE PELVIS
- •Approach to Reoperative Pelvic Surgery
- •Preoperative Planning
- •Timing
- •Patient Preparation
- •Functional Considerations
- •Intraoperative Conduct
- •Patient Positioning
- •Optimizing Visibility and Exposure
- •Access to the Pelvis
- •Ureter
- •Bladder
- •Rectal Stump
- •Vagina
- •Autonomic Nerves
- •Control of Bleeding
- •Drainage
- •SPECIFIC CLINICAL SITUATIONS
- •Reversal of Hartmann Procedure for Diverticulitis
- •Recurrent Rectal Cancer
- •Redo Ileoanal Pelvic Pouch Procedure
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •NUTRITIONAL ASSESSMENT
- •INDICATIONS FOR NUTRITIONAL SUPPORT
- •General Indications
- •Severe Malnutrition
- •Postoperative Nutrition
- •Colorectal Cancer
- •ESTIMATION OF NUTRIENT REQUIREMENTS
- •Calories
- •Protein
- •PREVENTION
- •Preventive Measures
- •Bowel Preparation
- •Prophylactic Antibiotics
- •Intact Anastomosis
- •Tension-Free Anastomosis
- •Well-Vascularized Anastomosis
- •Consideration for Diversion
- •Appropriate Use of Drains
- •Goal-Directed Hemodynamic Support
- •Evaluation
- •Nonoperative Interventions
- •Operation versus Observation
- •Open Abdomen
- •Return to the Operating Room
- •Suggested Readings
- •INTRODUCTION
- •WHAT DEFINES A LEAK?
- •PRINCIPLES OF MANAGEMENT
- •EARLY DIAGNOSIS
- •IMAGING
- •CRP LEVELS
- •ENDOSCOPY
- •VARIABLES DIRECTING MANAGEMENT
- •Location: Intraperitoneal versus Extraperitoneal
- •Symptoms: Sepsis versus Symptomatic versus Asymptomatic
- •Previously Diverted: Proximal Diverting Ostomy versus Nondiverted
- •LEAK MANAGEMENT TOOLS
- •ENDO-VACUUM ASSISTED CLOSURE
- •ENDOSCOPIC STENTS, CLIPS, AND GLUE
- •DIETARY COMPOSITION AND DELIVERY
- •Hospital-Based Diets
- •Clear Liquid Diet
- •Regular Diet
- •Low-Residue Diet
- •Oral Supplements
- •Liquid Formula Diets
- •Enteral Nutrition
- •Access for EN
- •Early Postoperative Feeding: “Fast Track”
- •Parenteral Nutrition
- •Access for PN
- •Concomitant EN and PN
- •Overfeeding
- •NEW DIRECTIONS
- •Immunonutrition
- •Preoperative Carbohydrate Loading
- •SUMMARY
- •Suggested Reading
- •BACKGROUND
- •TRANSANAL REPAIR TECHNIQUES
- •TURNBULL-CUTAIT PULL THROUGH
- •SUMMARY
- •Suggested Reading
- •INTRODUCTION
- •RISK MANAGEMENT
- •HEMORRHAGE
- •Steps Prior to Colonoscopy
- •Risk Factors for Bleeding
- •Prevention of Bleeding
- •Treatment of Bleeding
- •PERFORATION
- •Causes of Perforation
- •Diagnosis of Perforation
- •Management of Perforation
- •Suggested Readings
- •INTRODUCTION
- •PERTINENT ANATOMY
- •BLEEDING
- •Major Vessel Bleeding
- •Iliac Vessels
- •Minor Vessel Bleeding
- •Presacral Bleeding
- •Pelvic Packing
- •Suture Ligation
- •Thumbtacks
- •Muscle Fragment Welding
- •Bipolar Electrocautery
- •Hemostasis Step-by-Step Technique
- •Hemostatic Agents
- •Mechanical Hemostatic Agents
- •Active Hemostatic Agents
- •Flowable Hemostatic Agents
- •Fibrin Sealants
- •CONCLUSION
- •Selected Reading
- •INTRODUCTION
- •INFECTION
- •URETER
- •BLADDER
- •URETHRA
- •REPRODUCTIVE STRUCTURES
- •NERVES
- •BLOOD VESSELS
- •Suggested Readings
- •INTRODUCTION
- •GENERAL COMPLICATIONS
- •Contraindications
- •Peritoneal Access Complications
- •Pneumoperitoneum Complications
- •Thromboembolic Complications
- •Electrosurgical Complications
- •Positioning Complications
- •Bleeding Complications
- •Contamination
- •Anastomosis Complications
- •Urologic Complications
- •CONCLUSIONS
- •Suggested Reading
- •INTRODUCTION
- •OSTOMY CREATION
- •Preoperative Discussion and Consent
- •Siting the Stoma
- •Creating and Maturing the Stoma
- •End Ileostomy
- •Loop Ileostomy
- •COMPLICATIONS
- •Early Complications
- •Appliance Issues/Skin Irritation
- •Ischemia
- •Stoma Stenosis
- •Retraction
- •Late Complications
- •Parastomal Hernia
- •Prolapse
- •Stricture
- •Peristomal Pyoderma
- •Parastomal Ulcer
- •Abscess and Fistula
- •SUMMARY
- •Suggested Reading
- •PREOPERATIVE PREPARATION
- •Preoperative Counseling
- •Stoma Site Marking
- •POSTOPERATIVE MANAGEMENT
- •SPECIAL CONSIDERATIONS
- •Continent ileostomy
- •WOUND MANAGEMENT
- •POSTDISCHARGE FOLLOW-UP
- •COLOSTOMY IRRIGATION

RECTAL AND PARARECTAL REGION
151
S
u
g g e
ugestad KM, Lindsetmo RO, Reynolds H, etal. International trends in surgi-
A
cal treatment of rectal cancer. Am J Surg. 2011;201(3):353–358.
Delaney CP. Operative Techniques in Laparoscopic Colorectal Surgery. Phila-
delphia: Lippincott Williams & Wilkins; 2013.
Fazio VW, Zutshi M, Remzi FH, etal. A randomized multicenter trial to com-
pare long-term functional outcome, quality of life, and complications of
surgical procedures for low rectal cancers. Ann Surg. 2007;246(3):481–488,
discussion 488–490.
Heriot AG, Byrne CM, Lee P, etal. Extended radical resection: the choice
for locally recurrent rectal cancer. Dis Colon Rectum. 2008;51(3):284–291.
Jayne DG, orpe HC, Copeland J, et al. Five-year follow-up of the Medical
Research Council CLASICC trial of laparoscopically assisted versus open
surgery for colorectal cancer. Br J Surg. 2010;97(11):1638–1645.
S t
e d
R
e
a d i n g
MERCURY Study Group. Diagnostic accuracy of preoperative magnetic reso-
nance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779.
Peeters KCMJ, Tollenaar RAEM, Marijnen CAM, etal. Risk factors for anas-
tomotic failure aer total mesorectal excision of rectal cancer. Br J Surg.
2005;92(2):211–216.
e Beyond TME Collaborative. Consensus statement on the multidiscipli-
nary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013;100(8):1009–1014.
Tjandra JJ, Kilkenny JW, Buie WD, etal. Practice parameters for the manage-
ment of rectal cancer (revised). Dis Colon Rectum. 2005;48(3):411–423.
van der Pas MH, Haglind E, Cuesta MA, etal. Laparoscopic versus open sur-
gery for rectal cancer (COLOR II): short-term outcomes of a randomised,
phase 3 trial. Lancet Oncol. 2013;14(3):210–218.

T
L
R C
Maria
Widmar and Julio Garcia-Aguilar
INTR
ODUCTION
e treatment of early rectal cancer has been a controversial subject
for several decades. Radical proctectomy with total mesorectal excision (TME) is the gold standard for patients with tumors localized
to the bowel wall. e average local recurrence (LR) rate for stage I
rectal cancer aer TME approximates 2%, and 5-year survival is as
high as 95%. However, the morbidity associated with radical proctectomy is considerable, with postoperative complication rates
approaching 35%, and the mortality rate aer abdominal perineal
resection (APR) has been reported to be up to 5%. Both low anterior
resection (LAR) and APR are associated with signicant rates of longterm sexual and urinary dysfunction. Bowel function aer restorative
resection is compromised in at least one third of all patients, and aer
APR, creation of a permanent stoma is associated with an 80% risk of
long-term complications.
Local excision (LE) of rectal cancer was rst introduced by Kraske
in the 1880s. It did not become popular until the 1960s, when Mason
introduced the transsphincteric approach. e posterior transsphincteric approach is well suited to distal tumors located in the anterior wall of the rectum. In many centers, Mason’s procedure is the
preferred approach for the repair of recto-ureteral stulae because of
the access it provides. Fecal incontinence is the main complication,
although rates of less than 1% have been reported in some series.
Parks was the rst to describe transanal excision (TAE) without division of the anal sphincter for rectal cancer, using a specially
designed set of speculums to gain access to the tumor. In the 1980s,
a novel platform for transanal surgery was introduced, known as
transanal endoscopic microsurgery (TEM). Since then two additional
platforms, transanal endoscopic operation (TEO) and transanal minimally invasive surgery (TAMIS), have also been developed. In each
of these three approaches, the rectum is distended by insuation of
carbon dioxide and the tumor is removed under direct endoscopic
visualization, using either specially designed or conventional laparoscopic instruments. ese platforms allow the removal of tumors
located high in the rectum, beyond the reach of the conventional TAE.
e advantages of LE are lower rates of mortality and morbidity, with fewer long-term functional sequelae than radical resection.
However, LE is a compromise oncologically because it is associated
with a higher risk of LR and does not oer an opportunity to directly
examine local nodes. Current National Comprehensive Cancer
Network (NCCN) guidelines support the use of LE only in the treatment of carefully selected T1 rectal cancers. e oncologic outcomes
for local excision of T2 tumors remain unacceptably high.
Apart from local excision, two methods are used for local destruction of rectal cancer: endocavitary contact radiation (ECR) and
electrocautery. Both achieve destruction of the tumor, but neither
provides tissue specimens for pathologic examination. ECR has the
benet of being an outpatient procedure and is typically performed
with use of a local anesthetic and sedation; electrocoagulation
equires induction of general anesthesia and a hospital stay, similar
r
to LE. As TAE rises in popularity, these destructive techniques are
falling out of favor. However, ECR may still have a role, especially in
the treatment of frail patients.
In this chapter, we will describe local treatment of rectal cancer.
We will review patient selection and the techniques and outcomes
associated with these approaches. Given the intense focus and
research on LE for rectal cancer and its increasing popularity during
the past decade, we will preferentially focus on these modalities.
PREOPERA
Evaluation of all patients diagnosed with rectal cancer should include
a full medical history, physical examination, and baseline carcinoembryonic antigen serum level. Digital rectal examination allows direct
assessment of the location, size, and xity of low tumors and their
relationship to the sphincter complex.
Although most patients with newly diagnosed rectal cancer have
already had a colonoscopy before referral to a surgeon, a proctoscopy should be performed to conrm the location of the tumor. A full
colonoscopy should be performed before treatment for patients who
have not already had this procedure.
Endorectal ultrasound (ERUS), magnetic resonance imaging
(MRI), and computed tomography (CT) are routinely used in the
staging of rectal cancer. ERUS is perhaps the most valuable tool in
staging early rectal tumors. It provides high-resolution imaging of the
dierent histologic layers of the bowel wall and is excellent for delineating T stage in early-stage rectal cancers. It can also provide shortrange information about nodal status and demonstrate involvement
of the mesorectum. MRI with use of an endorectal coil also images
tumors within the bowel wall very accurately, although the technology is not widely used. Phased-array MRI has rapidly become the
gold standard in the preoperative staging of rectal cancer. It provides
high-resolution images of the rectum, mesorectum, surrounding pelvic structures, and the muscles of the pelvic oor, in multiple planes.
MRI is especially useful in staging advanced tumors, particularly in
dening the level of invasion into the mesorectum, nodal status, and
the relationship of the tumor to the mesorectal fascia. Unlike ERUS,
MRI does not dierentiate the T stage of tumors conned to the
bowel wall. A CT scan of the chest, abdomen, and pelvis should also
be performed to exclude metastatic disease.
e patient’s functional status and baseline bowel function should
be assessed before planning surgery. Some patients may not be good
candidates for TME because of signicant comorbidities, and some
may refuse a permanent colostomy. ese patients may benet from
transanal LE as a noncurative procedure. In other cases, poor preoperative bowel function and incontinence may diminish some of
the benets of LE, making TME with a permanent stoma the better
option.
TIVE EVALUATION
152

RECTAL AND PARARECTAL REGION
153
INITIAL SELECTION
e ideal candidate for LE has a supercial, mobile tumor that is
localized to the rectal wall (T1). If cure is the aim, there should be no
evidence of nodal involvement or distal metastases. Although tumor
size itself is not an absolute contraindication to LE, larger tumors are
oen more advanced and are more likely to have metastasized to the
regional lymph nodes. erefore, LE is not recommended for tumors
that encompass greater than 40% of the circumference of the rectal
wall or measure more than 4 cm in diameter.
In general, patients with tumors in the distal rectum are the best
candidates for LE. ese patients are most likely to benet from LE
because TME would require an APR with a permanent colostomy
or a coloanal anastomosis. Such tumors are also easier to reach with
conventional TAE techniques. However, the new transanal endoscopic platforms allow removal of tumors located in the mid and
upper rectum.
SURGIC
Patient Preparation
Patients should undergo mechanical bowel preparation and take
nothing by mouth for all of the surgical approaches described in the
following sections. Bowel preparation greatly facilitates visualization
during surgery. Sequential calf compression devices are applied, and
preoperative antibiotics are administered. A Foley catheter is placed
to decompress the bladder.
We routinely use perioperative thromboprophylaxis with unfractionated or low-molecular-weight heparin. At baseline, patients
undergoing LE for rectal cancer are at a higher risk of venous thromboembolism because of their cancer diagnosis. Overall, colorectal surgery, especially in the pelvis, carries a higher risk of venous
thromboembolism than does general surgery, but it is unclear if
these data are generalizable to transanal procedures. ere does not
appear to be any increased risk from use of the lithotomy or jackknife position during LE, and at least one large study has suggested
that this positioning is protective. Current recommendations by the
American College of Chest Physicians support thromboprophylaxis
in these patients, with optimal management consisting of combined
use of low-dose heparin and compression devices.
Transanal Excision
G
ood visualization is crucial to a successful TAE. e surgeon should
wear a headlight. Positioning is aimed at providing adequate exposure to the tumor. For anterior tumors, the patient is in the prone
jackknife position. e operating table should be in a slight Trendelenburg position. For posteriorly situated tumors, the patient is in
a modied lithotomy position, again with the table in the Trendelenburg position. Care should be taken to provide adequate padding
at all weight-bearing points. TAE can oen be performed with use
of monitored sedation, although general anesthesia may need to be
induced depending on the tumor size and location.
e buttocks are taped apart and a Lone Star retractor (CooperSurgical, Trumbull, Conn.) is used to open the anus, especially in the
setting of very distal tumors. Hill-Ferguson, Pratt bivalve, or other
retractors are used to expose the rectum. For more proximal tumors,
narrow Deaver and short Wiley retractors are helpful.
We begin by marking the intended incision line with cautery,
with at least 1-cm margins around the tumor. A local anesthetic
with epinephrine can be inltrated under this margin for additional
hemostasis. Especially for proximal tumors, stay-sutures are placed
laterally and beyond the incision line in order to pull the tumor
closer to the anal orice. A full-thickness excision is carried out
AL TECHNIQUE
with electrocautery, beginning at the far end (the more proximal)
and working distally. Excision extends into the mesorectum, and
the specimen is undercut through the perirectal fat. Some surgeons
advocate taking a conical margin of the entire mesorectum. During
deeper excision anteriorly, care must be taken to avoid injuring the
vagina in females and the prostate in males.
e wound should then be extensively irrigated with water. e
defect is closed with full-thickness bites transversely; these bites can
be with continuous or interrupted sutures, depending on the tension of the wound. Proctoscopy should be performed to conrm the
patency of the lumen.
Two doses of prophylactic antibiotics are typically administered
in the perioperative setting—one dose within 30 minutes of beginning the procedure, and one dose postoperatively. However, some
centers routinely prescribe additional prophylaxis. In a single-institution series from 2010, Bignell and colleagues reported a pelvic sepsis
rate of 6.5% aer TEM for tumors within 2 cm of the dentate line.
For more proximal tumors, the rate was 0.5%. As a result, it is now
routine for patients with very distal tumors to be prescribed 5 days
of antibiotic prophylaxis postoperatively. Other groups have reported
use of similar extended courses of antibiotics.
ransanal Endoscopic Microsurgery/Transanal
T
Endoscopic Operation
e TEM platform is manufactured by the Richard Wolf Medical
Instruments Corporation (Vernon Hills, Ill.). It includes a selection
of large-bore operating proctoscopes, with some beveled and some
at. e proctoscope is tted with a carbon dioxide insuation
system and binocular optics that provide tridimensional visualization. e TEM instruments, including a grasper, electrocautery, and
other devices, are specically designed and angled for use in the
proctoscope.
More recently, e Storz Corporation (El Segundo, Calif.) has
developed a simplied TEO platform that also uses a large-bore
operating rectoscope. However, the insuation, instrumentation,
and optics are those of conventional laparoscopy. is platform is less
expensive but does not provide tridimensional visualization and has
less sophisticated instrumentation than the TEM platform.
As with TAE, patients are placed in either the prone jackknife or
modied lithotomy position; the goal is to have the tumor positioned
inferiorly in the surgeon’s eld of view. Lateral tumors may require
the patient to be in the lateral decubitus position. Patients are positioned with the aid of beanbags. roughout the case, the operating
table may have to be moved sideways or placed in the Trendelenburg
position for optimal visualization, so it is important that the patient
be well secured to the table.
Once the patient is positioned, the TEM/TEO platform is
mounted onto the table by means of a support arm, and aer gentle
anal dilatation, the proctoscope is inserted. e rectum is insufated to 15 to 26 mm Hg. Full-thickness excision is performed,
as described in TAE, but with use of the specialized instruments
inserted through the proctoscope. At the conclusion of the excision,
the defect is closed with interrupted sutures. In cases in which there
is too much tension, or when the cavity le behind in the rectum
aer closure is very large, the defect may be le open to prevent
abscess and dehiscence. Leaving the defect open is not an option
if there is entry into the peritoneal cavity; such defects must be
closed. Meticulous hemostasis should be achieved because bleeding
s among the most common postoperative complications. Luminal
i
patency is checked by proctoscopy at the conclusion of the case,
and the rectum is irrigated and packed. Postoperative antibiotics
are administered.
Neither TEM nor TEO is well suited to resection of very distal
tumors because their platforms cannot be stably mounted, nor can a
good seal be created. However, both are ideal approaches for proximal tumors. e surgeon is able to advance the scope to the level of

154
t
he tumor, permitting excision under direct visualization. e use of
specialized and/or laparoscopic instruments allows for full-thickness
resections as high as the peritoneal reection (which would not be
possible by TAE). Because entry into the peritoneal cavity is possible
and occasionally requires conversion to an abdominal approach in
order to close the resultant wound, most TEM and TEO procedures
are performed aer induction of general anesthesia.
LocaL
TmenT of recTaL cancer
Trea
TABLE 31-1: Clinical T1N0 Rectal Cancer Treated by
Surgery Alone: Five-Year Local Recurrence, Distant
Recurrence, and Disease-Specific Survival in Studies
from 2004–Present
Surgical Appr
LE* 6–12 0–5 75–95.8
oach LR (%) DR (%) DSS (%)
ransanal Minimally Invasive Surgery
T
e most recent innovation in transanal excision is TAMIS, which
uses the laparoscopic SILS Port (Covidien USA, Bolder, Colo.) as the
platform. Aer the patient is positioned as indicated in the TEM and
TEO procedures, the SILS Port is lubricated and inserted into the rectum. e rectum is insuated, and traditional laparoscopic instruments are used for the resection. is technique has also been used in
conjunction with robotic surgery. As with TEM and TEO, very distal
tumors are not amenable to TAMIS.
MANAGEMENT OF THE SPECIMEN
er LE of a rectal cancer, the specimen should be pinned down
A
with orientation marks and sent for pathologic examination. Margins
should be inked. As mentioned previously, nal pathologic examination is the ultimate determinant of whether LE is sucient or if
TME is necessary. Increasing evidence suggests that T1 tumors, especially those restricted to the upper two thirds of the submucosa (sm1
and 2), are the best candidates for LE alone, whereas more advanced
tumors should be treated with TME. Specic high-risk features may
prompt TME aer LE; these features are described in further detail in
a subsequent section.
FOLLO
R
egardless of the LE approach, follow-up is aimed at early detection
of local and distant recurrences. Most recurrences aer treatment of
stage I rectal cancers occur within 1.1 years aer LE, though this time
frame may be delayed to 2.2 years if adjuvant therapy is provided.
Nearly all recurrences happen within 5 years of surgery. Accordingly,
follow-up must be rigorous and includes digital rectal examination,
proctoscopy, and ERUS every 4 months for 3 years, then every 6
months for 2 additional years. Suspicious lesions should be biopsied. Follow-up CT scans should be performed annually for 5 years.
NCCN guidelines recommend that the carcinoembryonic antigen
serum level should be determined every 3 to 6 months for 2 years,
and then every 6 months for a total of 5 years aer LE of T2 lesions.
RESUL
Local Excision f
C
urrent NCCN guidelines support LE only for T1 tumors with no
high-risk features. A summary of recent studies reporting LR, distant
recurrence (DR), and disease-specic survival (DSS) for clinical T1
rates of 2% to 29% for T1 tumors treated with TAE. In a retrospective
study from Memorial Sloan Kettering Cancer Center with a lengthy
follow-up period, Paty and colleagues conrmed these ndings; however, they suggested that the mortality rates aer TAE for T1 tumors
may be underestimated in many studies because the interval between
surgery and death may be as long as 10 years. Studies from the past
decade, shown in Table 31-1, also report higher rates of LR compared
with TME, with long-term similar DSS rates of 87% to 100%.
W-UP
TS
or T1N0 Rectal Cancer
TAE 8–23.5 2.6–13.2 87–100
TEM/TEO/TAMIS 0– 24 4.8– 7.5 89–100
TME 0– 6 2.6– 7.9 87–100
pecic LE approach was not specied.
*A s
DR, Distant recurrence; DSS, disease-specic survival; LE, local excision;
LR, local recurrence; TAE, transanal excision; TAMIS, transanal minimally
invasive surgery; TEM, transanal endoscopic microsurgery; TEO, transanal
endoscopic operation; TME, total mesorectal excision.
TEM, TEO, and TAMIS may produce improved LR and survival
rates in persons with T1 rectal cancer compared with traditional TAE.
A randomized trial published in 1996 comparing TEM and TME for
T1 tumors reported an LR rate of 4% and a 5-year survival rate of
96% aer TEM; this nding closely parallels the results reported aer
TME. As shown in Table 31-1, recent studies show signicant het-
erogeneity in outcomes, yet at least two groups have reported no LRs
with the use of these advanced platforms. Of the few studies directly
comparing TAE and TEM for T1 tumors, a series from 2002 showed
higher LR rates for TAE compared with TEM in cancer resections
(15% vs. 10%) and for cancer and adenoma resections combined
(27% vs. 8.9%). ese encouraging results suggest that TEM, and
possibly TEO and TAMIS, may improve the LR rates of local excision for T1 tumors, while certainly resulting in improved functional
outcomes compared with TME.
Local Excision f
lone for cT2N0 rectal cancer leads to high rates of LR and
LE a
decreased survival compared with TME. Surprisingly, a recent
national study reported an increase in LE in treating not only T1
tumors but also T2 tumors. is nding is perhaps a reection that,
for some patients, the benets of LE compared with radical mesorectal resection (TME) may outweigh the oncologic risk. Table 31-2
summarizes LR, DR, and DSS rates reported by recent studies, including T2 tumors treated by LE alone. In almost all studies, the LR and
DR rates aer all forms of LE were higher than aer TME. Although
one study reported 5-year DSS that was comparable with TME, it is
dicult to generalize these ndings given the signicant increase in
recurrent disease aer LE that is documented by every other study.
Since the 1990s, several groups have attempted to improve poor
oncologic results by adding chemoradiation therapy (CRT) to LE in
the treatment of T2N0 tumors. Multimodality treatment consisting
of CRT and surgery has been widely accepted for stage II and III
rectal cancer since 1990. In the German rectal cancer study, neoadjuvant chemoradiation was associated with decreased LR and improved
quality of life compared with that following adjuvant therapy. On the
basis of these ndings, it has been extrapolated that CRT in conjunction with LE for treating T2N0 tumors may also decrease the high LR
rate associated with LE alone.
Table 31-3 summarizes recent studies of cT2N0 tumors treated
by combination CRT and LE. Overall, the addition of chemoradiation to TAE decreases LR rates from 33% to 42.3% to 0% to 18%.
With the advanced surgical platforms, the LR rate is as low as 0% to
8% when CRT is added, compared with 25% to 50% without CRT.
In the SEER database study (included in Table 31-2), analysis of a
or T2N0 Rectal Cancer

TABLE 31-2: Clinical T2N0 Rectal Cancer Treated by
Surgery Alone: Five-Year Local Recurrence, Distant
Recurrence, and Disease-Specific Survival in Studies
from 2004–Present
Surgical Appr
LE* NR NR 85.2-93.1
TAE 33-42.3 7.7 76.9
TEM/TEO/T
TME 7.5 2.5 90
pecic LE approach was not specied.
*A s
†
verall survival.
O
DR, Distant recurrence; DSS, disease-specic survival; LE, local excision; LR,
local recurrence; NR, not reported; TAE, transanal excision; TAMIS, transanal minimally invasive surgery; TEM, transanal endoscopic microsurgery;
TEO, transanal endoscopic operation; TME, total mesorectal excision.
T
ABLE 31-3:
b
y CRT and Surgery: Five-Year Local Recurrence,
oach LR (%) DR (%) DSS (%)
†
AMIS 25-50 50 NR
†
-94.1
Clinical T2N0
Rectal Cancer Treated
Distant Recurrence, and Disease-Specific Survival
in Studies from 2004–Present
Surgical Appr
LE* 18 12 64-92.5
TAE 10-18 10-12 82.4-90
TEM/TEO/TAMIS 0-8 2.4-17.6 82-93
TME 6 4 94
*A s
pecic LE approach was not specied.
DR, Distant recurrence; DSS, disease-specic survival; LE, local excision;
LR, local recurrence; TAE, transanal excision; TAMIS, transanal minimally
invasive surgery; TEM, transanal endoscopic microsurgery; TEO, transanal
endoscopic operation; TME, total mesorectal excision.
oach LR (%) DR (%) DSS (%)
RECTAL AND PARARECTAL REGION
eterogeneity exists in the studies examining salvage procedures
h
155
after LE. In 2012, Stipa and colleagues reported on 144 patients
with T1 to T3 tumors resected by LE, of which 44 recurred (31%).
Of the 27 patients with recurrent tumors treated by salvage TME,
the overall 5-year survival was 69%. The group from Memorial
Sloan Kettering Cancer Center specifically focused on stage I
tumors and reported 49 successful salvage surgeries. However,
more than half of these patients (55%) required extensive opera-
53% and is well below the expected survival for patients presenting
with stage I tumors. A recent study from the Netherlands reported
similar results, with only 58% DSS in patients who underwent
salvage surgery at 3 years; however, unlike the Memorial Sloan
Kettering Cancer Center experience, none of these cases required
multivisceral resections.
Salvage TME aer LE may be considered in several other scenarios. Proponents of “immediate salvage” argue that positive margins
aer LE and high-risk features on the nal pathologic examination
should prompt TME within 4 to 6 weeks of LE. Tumors characterized by lymphovascular invasion, poor dierentiation, or mucinous components are more likely to recur and therefore should not
be treated by LE; this appears to be the case even if the resection
specimen itself has negative margins and no positive lymph nodes.
For this subset of patients with more aggressive tumors, LE would
function essentially as an excisional biopsy. Preliminary studies
have shown nearly 89% survival rates in patients who undergo
“immediate salvage.”
e concern in both immediate and delayed salvage TME is
whether a complete oncologic resection can be achieved aer transanal LE. Aer all, in ideal circumstances, LE techniques involve
full-thickness resections and possible breach of the mesorectum. Violation of this “holy plane” may compromise the integrity of an oncologic resection of the rectum at a later date. In addition, some studies
show increased complication rates aer salvage surgery, including
high rates of permanent stoma, even when salvage is performed in
the immediate setting.
TERNATIVE TO LOCAL EXCISION:
AL
ENDOCAVITARY CONTACT
RADIATION
all subset of patients who had undergone CRT and LE showed
sm
oncologic equivalence to radical resection at 5 years. A randomized trial published in 2012 also showed equivalent DSS, LR, and
DR rates among 100 patients undergoing either TME or LE aer
neoadjuvant CRT.
It is important to note that a retrospective analysis of outcomes
comparing LE and TME aer CRT for T2NO rectal cancer is questionable given the heterogeneity of the literature. In addition, it
is dicult to identify the true impact of this approach on survival.
e complications of neoadjuvant CRT may outweigh the improved
oncologic benets for some patients, who would not have undergone
irradiation had they proceeded directly to TME. In light of these controversies, the oncologic outcomes of CRT and LE for T2N0 rectal
tumors are currently being studied in a prospective multi-institution
clinical trial (ACOSOG Z6041).
Salvage Resection after Local Excision
itical issue in determining the feasibility of LE for rectal can-
A cr
cer is management of recurrent cancer and determining whether
outcomes in these “salvaged” patients are worse than if the patients
had undergone TME from the outset. LR is the most common
form of recurrence after LE, and it is a clear indication for salvage
TME. Overall, the survival rates for these patients appear to be
lower than for those who undergo TME first. However, significant
J
ean Papillon in Lyon, France, popularized ECR for early stage rectal
cancer from 1950 to 1990. e technique involves the use of the Phillips RT 50 machine, with an endorectal probe capable of delivering
up to 20 Gy in 2 to 3 minutes directly onto the tumor. Only light
sedation is necessary for most patients, and the procedure can be performed on an outpatient basis.
According to Papillon’s protocol, ECR is restricted to patients
with T1/T2, N0 tumors that measure less than 5 cm in diameter
and encompass less than 50% of the bowel wall circumference.
Papillon reported an LR rate of 10% in 312 patients with stage I
disease and 75% 5-year survival. Specifically, in 158 patients with
T1N0 tumors, the 5-year LR rate was 3.8%, and the nodal failure
rate was 4%. In the United States, authors of a single-center study
of 40 patients with T1N0 tumors reported an LR rate of 22.5%.
Additional applications have included ECR after transanal excision, as well as combined external beam radiotherapy and ECR
for T2 tumors, with some success. In a series of 40 patients with
cT2N0 tumors, the 5-year LR rate was 20%, and 5-year overall
survival was 80%.
Despite these encouraging results, ECR has never gained widespread popularity. In addition, production of the Phillips RT 50
machine was discontinued in the 1980s, and thus in the 1990s, few
centers had expertise in this technique. In 2009, the new Papillon 50
machine was introduced, including some functional improvements
compared with the original model. At least three clinical trials are
currently under way to assess outcomes aer ECR for rectal cancer.

156
LocaL
TmenT of recTaL cancer
Trea
CONCLUSIONS: ALGORITHM FOR
TREA
Figur
cer. In summary, LE appears to be adequate for T1 tumors without
high-risk features. LE alone is not adequate treatment for T2 tumors
in patients who are able to undergo TME/radical resection. Clinical
trials are under way to determine if the addition of neoadjuvant CRT
improves oncologic outcomes aer LE for T2 tumors. By sparing
patients a radical proctectomy, this approach will likely lead to fewer
complications, better postoperative bowel function, and better quality of life.
LE with positive margins is a clear indication for salvage TME, but
this procedure may involve a larger resection and increased complication rates. Furthermore, in this setting, long-term outcomes appear
TMENT BY LOCAL EXCISION
e 31-1 shows an algorithm for LE in the treatment of rectal can-
T1N0
to be less favorable than in patients who undergo index TME. e
preliminary results of immediate salvage aer LE for tumors with
high-risk pathologic features are encouraging, although future studies are needed to validate these ndings.
Overall, acceptance of LE in the treatment of rectal cancer continues to grow worldwide. Current investigations are aimed at
expanding its application to higher staged and more proximal tumors
through innovative platforms and combined modality treatment.
Ultimately, the key to treating rectal cancer adequately by LE lies in
careful patient selection. Optimal imaging and accurate staging is
crucial. An evolving understanding of the prognostic value of tumor
response to neoadjuvant therapy is also promising. It is hoped that
these approaches will one day lead to excellent oncologic outcomes
while reducing the signicant morbidity associated with the current
gold standard, TME.
T2N0
(investigational)
Neoadjuvant CRT
TAE
TME
TEO
TAMIS
FIGURE 31-1
transanal minimall
Alg
– Margins
–High-risk
features
Observe
orithm for local excision in the treatment of rectal cancer. CRT, Chemoradiation therapy; TAE, transanal excision; TAMIS,
y invasive surgery;
, transanal endoscopic operation;
TEO
+ Margins
Reexcision or
salvage
resection
+High-risk
features
Observe or
salvage
resection
total mesorectal excision.
TME,
+Recurrence
Salvage
resection

L R
R C:
M
V
anessa W. Hui, Harvey G. Moore, and José G. Guillem
ODUCTION
INTR
An estimated 40,000 new cases of rectal cancer were diagnosed in the
United States in 2015, encompassing almost one third of all newly
diagnosed colorectal cancers. In 4% to 19% of these patients, pelvic
recurrence will develop aer curative resection. ese patients oen
experience signicant pelvic pain, dysesthesia, tenesmus, and other
local complications that severely impair quality of life. Early diagnosis and aggressive surgical treatment of locally recurrent rectal cancer
may be justied in carefully selected patients and may possibly palliate these problems, as well as potentially prolong disease-free and
overall survival.
NOMENCLA
RECURRENCE
S
everal classication systems have been used to describe pelvic
recurrences. e most useful of these systems is an anatomic classication of recurrence because it facilitates discussion of possible
treatment options and allows for meaningful comparisons of prognosis (Fig. 32-1).
e anatomic classication of recurrence separates the pelvis into
axial, anterior, posterior, and lateral regions. e axial region includes
both mucosal and perirectal so tissue recurrences, which may occur
aer a transanal or transsphincteric excision, at the anastomosis aer
a low anterior resection (LAR) with primary reconstruction, and in
the mesorectum. Axial recurrences also include recurrence of disease in the perineum aer an abdominoperineal resection (APR),
although these recurrences are relatively rare. Anterior recurrences
involve the genitourinary tract, including the vagina, uterus, urinary
bladder, and/or distal ureters in women and the seminal vesicles,
prostate, urinary bladder, and/or distal ureters in men. e sacrum
and/or pelvis are involved in posterior pelvic recurrences; whereas
lateral recurrences can invade into adjacent pelvic sidewall structures
such as the iliac vessels, pelvic ureters, obturator lymph nodes, adjacent nerves, and muscle, as well as the bony pelvis. It is important
to note that pelvic recurrences may oen involve multiple anatomic
regions, and the degree of involvement in each will dictate whether
the patient is a candidate for radical salvage resection.
CLINIC
SUSPECTED PELVIC RECURRENCE
P
atients who have had surgery for rectal cancer are followed up clinically at regular intervals. Asymptomatic recurrences may be found
by digital examination, with routine imaging, or upon endoscopy.
Symptoms such as a change in bowel habits, rectal bleeding, pain,
and obstipation may herald a local recurrence, which is likely to be
more extensive than recurrences found incidentally. Vaginal bleeding
TURE OF PELVIC
AL EVALUATION FOR
F-
or urinary symptoms may reect involvement of the genitourinary
tract, whereas perineal pain or a persistent perineal sinus aer APR
may reect a perineal recurrence or disease involving the sacrum.
Leg edema and/or sciatic pain are ominous symptoms and suggest
extensive pelvic sidewall involvement.
Physical examination should include a thorough examination
of the abdomen, including palpation for an enlarged liver or tumor
mass. A digital rectal examination is essential for any patient who has
had LAR or local excision because anastomotic recurrences may be
palpable and the digital examination will provide information with
regard to the size of the recurrence, its location relative to the upper
part of the anorectal ring, and the degree of xation to the luminal
wall. is information may indicate involvement of surrounding pelvic structures. Endoscopy may help dene the proximal margin of
the recurrence, the extent of the luminal involvement, and the overall extent of disease. Examination of the groin and supraclavicular
regions is required to exclude adenopathy. Assessment of neuromuscular function in the lower extremities can identify decits resulting
from peripheral nerve involvement by lateral tumor recurrence. In
women, a bimanual pelvic examination may reveal disease involving
the rectovaginal septum, vagina, uterus, and adnexal structures. e
perineal region aer APR also should be closely examined to detect
tenderness, a mass, or a sinus/stula. A pelvic examination in women
aer APR facilitates the detection and extent of disease involvement.
In patients with pelvic recurrence for whom radical surgery is being
considered, a complete colonoscopy should be performed preoperatively to rule out synchronous neoplasms.
Although the interpretation of endorectal ultrasound (ERUS)
images is subjective, especially in patients who have already undergone a surgical procedure, ERUS can detect pelvic masses and
enlarged lymph nodes and can be used for an ERUS-directed biopsy
of masses. In addition, a transvaginal ultrasound may be used in
female patients who have undergone APR.
Computed tomography (CT) with use of both intravenous and
oral contrast material may be useful for the detection and staging of
local recurrence, as well as distant metastases. Asymmetric thickening of the bowel wall, obliteration of peri-anastomotic fascial or
fat planes, a presacral or lateral sidewall mass, or enlarged regional
lymph nodes are evidence of local recurrence. However, both surgery
and radiation may lead to brosis and linear streaks in the perirectal
fat, an appearance indistinguishable from a true recurrence. Magnetic resonance imaging (MRI) adds further anatomic detail pertaining to the depth of tumor inltration into the rectal wall and has
a negative predictive value of 93% to 100% for tumor invasion into
adjacent structures in cases of locally recurrent rectal cancer. is
additional information may be useful in preoperative planning and
assessing the extent of an en bloc resection necessary to achieve a
curative resection.
Positron emission tomography with CT (PET-CT) is an imaging modality that combines both anatomic and metabolic information for detecting recurrent disease. PET utilizes the glucose analog
157

158
Anterior
(GU)
FIGURE 32-1
ecurrence can be classified on the basis of the anatomic region(s)
r
of the pelvis involved with disease. Axial recurrences can involve (1)
the anastomosis,
the perineum after abdominoperineal resection. Anterior recurrences
involve the genitourinary (GU) tract including the bladder, vagina,
uterus, seminal vesicles, and prostate. Posterior recurrences involve the
sacrum and presacral fascia. Lateral recurrences (not shown) involve
the soft tissues of the pelvic sidewall and the lateral bony pelvis.
-uorodeoxyglucose to distinguish postoperative brosis and
18F
LocaLLy RecuRRent RectaL canceR:
2.
1.
3.
Axial
1. Anastomotic
2. Mesorectal
3. Perineal
Regions of rectal cancer pelvic recurrence. Pelvic
(2) the mesorectum or perirectal soft tissue, or (3)
Posterior
(sacrum)
Manage
radiation changes from hypermetabolic cancer cells. PET-CT may
also identify distant metastases that preclude an attempt at curative
resection. Although not typically used for surveillance aer primary
rectal cancer resection, PET-CT may be helpful in select cases when
information from other examinations regarding local and distant
recurrence is inconclusive.
MANA
GEMENT OF PELVIC
RECURRENCE
N
ineteen percent to 52% of local recurrences are conned to the pelvis and thus are amenable to potentially curative repeat resection.
Aer the diagnosis of pelvic recurrence is conrmed, the disease presentation usually falls into one of four categories based on the presence of extrapelvic disease, resectability of the recurrence, and the
presence of symptoms. During the course of therapy, it is important
to be alert to changes in symptoms because progression may require
an alteration in management. Patient age and comorbidities are also
important considerations in formulating a treatment strategy.
ory I: Asymptomatic Local and Distant
Categ
Recurrence
ecause curative options for patients with concomitant local and
B
distant recurrences are few, treatment should be oered judiciously,
particularly for young asymptomatic patients. A small, highly select
Ment
and Fo
LLo
w-up
group may benet from resection of two sites of isolated disease (e.g.,
pelvis and lung or liver). Data supporting the ecacy of this approach
in curing patients with recurrence are limited.
ory II: Symptomatic Local Recurrence in the
Categ
Presence of Distant Disease
e goal in treating symptomatic local recurrence in the presence
of distant unresectable metastases should be to minimize morbidity
and maximize palliation. Treatment options for patients with rectal
bleeding from a local recurrence include fulguration, radiation, combined modality therapy (CMT), or palliative resection. Radiation or
CMT also may be eective for the palliative treatment of pain, neurologic symptoms, and symptoms related to mass eect. Safe palliative
options for patients with bowel obstruction due to recurrence within
10 to 12 cm of the anal verge include fulguration, laser ablation, gastrointestinal bypass, diversion, and endoscopic stenting.
ory III: Unresectable, Isolated Local
Categ
Recurrence
T
reatment options for patients with isolated, unresectable pelvic
recurrence who have not received large doses of external beam radiation include preoperative CMT. A trial of external beam radiation
with radiosensitizing 5-uorouracil–based chemotherapy may result
in a response that allows resection with negative histologic margins.
Limitations include entrapment of small bowel in the pelvis aer the
initial resection and compromise in luminal diameter with impending obstruction. In these persons, a diverting colostomy or ileostomy
will prevent the development of clinical obstruction while the patient
receives CMT.
ory IV: Resectable Isolated Local Recurrence
Categ
urgical resection is the only curative option for patients with iso-
S
lated pelvic recurrence. e likelihood of a successful resection and
the surgical options available to these patients are dictated, in part,
by their primary procedure and the region of the recurrence. Patients
may benet from preoperative therapy in the form of radiation, chemotherapy, or CMT as a way of achieving an R0 resection (generally
dened as complete resection with negative microscopic margins),
which is associated with long-term local control.
Endoscopic stenting for stenosing recurrent rectal cancer may be
considered as a temporary “bridging” approach for the facilitation
of bowel preparation. However, if the stent remains in situ for a long
time it may migrate distally, leading to worsening tenesmus and pain.
Patients with a near-obstructing recurrence are at signicant risk for
progression to complete obstruction as a result of the initial swelling
and edema that occur with external beam radiation and thus may
benet from a “bridging stent” or diverting ostomy before radiation
treatment begins.
Cystoscopy with bilateral ureteric stent placement is recommended for all patients about to undergo surgery for a pelvic
recurrence, especially when bladder involvement is suspected.
The operative approach begins with an exploratory laparotomy,
at which time up to a third of cases will be found to be unresectable. If unresectable extrapelvic and/or locally recurrent disease is
detected and confirmed upon frozen section testing, a diverting
loop colostomy or ileostomy is an option in cases of impending
obstruction.
Overall, 32% to 64% of patients with locally recurrent rectal cancer are able to undergo a curative R0 resection. Reported 5-year overall survival for patients undergoing R0 resection ranges from 30% to
72%, with median overall survival signicantly higher than for persons who undergo noncurative resections (7.1 vs. 1.9 years).

RECTAL AND PARARECTAL REGION
159
Axial Recurrences
Axial recurrences may represent a failure to obtain adequate distal margins during LAR, tumor implantation into the mesorectum
during local excision, or perineal tumor implantation during APR.
Sphincter preservation may be an option for high axial-anastomotic
recurrences. However, the quality of life of persons undergoing a
resection of locally recurrent disease with sphincter preservation
may be diminished. Furthermore, signicant lateral extension oen
requires a combined abdominal-perineal approach to ensure negative circumferential resection margins. Although wide local excision
of a perineal so tissue recurrence aer APR may render the patient
free of disease, the perineal recurrence is oen a harbinger of disease
deeper in the pelvis, which would require a combined abdominalperineal approach to ensure a curative R0 resection. Regardless of the
extent of the surgery, it is important to avoid inadvertent injury to
the small bowel and other surrounding structures. e outcome for
patients with recurrent disease limited to the bowel wall is much better than for patients with disease involving other regions.
Anterior Recurrences
Recurrences involving the genitourinary tract require en bloc removal
of involved pelvic viscera to achieve negative histologic margins. A posterior pelvic exenteration (i.e., an APR with total abdominal hysterectomy, bilateral salpingo-oophorectomy, and posterior vaginectomy) is
indicated for anterior pelvic recurrence in women with isolated uterine/
vaginal involvement but no bladder involvement. A partial cystectomy
or total pelvic exenteration (TPE) is required when the tumor involves
the bladder. In women who have undergone a hysterectomy, an anterior recurrence generally mandates a TPE because usually no tissue
plane exists between the recurrence and the bladder. Aer cystectomy,
urinary drainage is provided by either an ileal conduit or a continent
pouch. Although resection of the anterior viscera may facilitate negative
resection margins anteriorly, obliterated anatomic planes secondary to
previous surgery (especially APR) and radiation may limit the ability to
ensure negative posterior and lateral resection margins. For this reason,
whenever possible, the initial surgical approach should be in an unoperated plane where it has not been violated by previous surgery.
Pelvic exenteration is a technically challenging procedure with
signicant morbidity and should not be attempted unless a curative
R0 resection is anticipated. Complication rates aer TPE range from
37% to 100%, with an in-house hospital mortality rate of 0% to 25%.
However, more recent studies suggest that perioperative mortalities can be as low as 0% to 5.5%. In carefully selected patients, curative pelvic exenteration may be associated with a 3-year local repeat
recurrence rate of 40% to 60%, a 3-year disease-free survival rate of
22% to 57%, and a 3-year overall survival rate of 32% to 79% with
a median survival of 2.4 years (some investigators report a diseasespecic survival rate as long as 4 years).
Posterior Recurrences
In select posterior recurrences where sacral invasion is limited to the
presacral fascia or supercial periosteum, an en bloc resection by
periosteal elevation may achieve negative margins. When bony invasion of the sacrum is present, R0 resection can still be achieved using
a combined abdominal-sacral resection. A sacrectomy may be performed in combination with an APR or pelvic exenteration depending on the extent of pelvic disease. Such resections usually entail a
lengthy operation with signicant blood loss. e most potentially
morbid aspect of an abdominal-sacral resection is the bony transection, which involves a signicant risk of hemorrhage and sacral
nerve root damage. Major morbidities associated with this procedure
include intestinal and urinary stula, wound complications, pulmonary embolus, and bladder dysfunction.
Bladder dysfunction is related to the level of sacral transection.
Sacral transection below S3 does not usually aect urinary continence, but mild urinary dysfunction occurs with unilateral division
of S2 or S1. Bladder dysfunction occurs when both S2 nerve roots are
resected and complete bladder denervation occurs aer bilateral division of the S1 nerve roots. e feasibility and safety of sacral resection
has been demonstrated by several centers, with a reported in-hospital
mortality of 0% to 3%.
Lateral Recurrences
Recurrences along the pelvic sidewall are the least likely to be salvaged by resection. ese tumors oen adhere to the bony pelvis and/
or invade the sciatic nerve. Patients may present with disabling pain
radiating to the buttocks, perineum, and posterior thighs. Ureteral
obstruction due to recurrent disease is also associated with a low likelihood of R0 resection. Iliac nodal disease can be removed en bloc
with a local so tissue resection that may involve a partial ureterectomy and partial resection of major arteries and veins.
THE R
OLE OF CHEMORADIATION FOR
PELVIC RECURRENCE
eoadjuvant therapy with chemoradiation or chemotherapy alone
N
should be considered in all cases of locally recurrent rectal cancer
because it may help salvage xed inoperable or borderline resectable
recurrences and possibly improve survival. Compared with radiation
alone, neoadjuvant chemoradiation has been shown to improve the
likelihood of resectability, prolong the time to repeat recurrence, and
lengthen overall survival. e ecacy of chemotherapy for treating a
local recurrence aer rectal cancer resection and preoperative CMT
may be limited.
Intraoperative radiation therapy (IORT) allows the delivery of a
large dose of radiation directly to the bed of resection without aecting healthy surrounding tissues. IORT can be delivered to areas of
questionable or microscopically positive resection margins either at
the time of resection via electron beams from a linear accelerator or
aer surgery by implantation of radioactive sources (brachytherapy).
At our institution, IORT is delivered with high-dose-rate brachytherapy via a exible remote aerloader called the Harrison-AndersonMick applicator. is applicator conforms well to the tumor bed and
is capable of delivering the maximum dose to the proposed target
area while sparing the surrounding healthy tissues. e procedure is
performed in a dedicated shielded operating room to avoid moving
the patient during the operation.
IORT is generally combined with neoadjuvant chemoradiation
in patients with locally recurrent rectal cancer. Patients undergoing
a curative salvage resection with neoadjuvant chemoradiation and
IORT have a 5-year overall survival of 46% to 56% and 5-year local
control of 44% to 69%. Orthovoltage and photon beam IORT are
alternative techniques currently under investigation.
Associated radiation toxicity remains a major issue, and despite
using lead shields to protect adjacent so tissues such as the ureter,
iliac vessels, and sciatic nerve, these structures may nevertheless be
damaged by the combination of extensive surgery and radiation therapy. Researchers at our institution are currently investigating the use
of radiation dose painting during high-dose rate IORT as a means
of enhancing local control while minimizing radiation exposure and
toxicity to other sites.
PREOPERA
TIVE AND
INTRAOPERATIVE CONSIDERATIONS
G
iven the complexity of locally recurrent rectal cancer, a multidisciplinary treatment approach is essential. ese cases are best
presented and discussed in a multidisciplinary team conference in
collaboration with radiologists, pathologists, surgeons, and medical
and radiation oncologists in order to develop an individualized treatment strategy and sequence. Because of the extent of involvement

160
LocaLLy RecuRRent RectaL canceR:
Manage
Ment
and Fo
LLo
w-up
TABLE 32-1: A Multidisciplinary Approach to
Recurrent Rectal Cancer
Specialist Role
adiologist Preoperative planning
R
Pathologist Preoperative and intraoperative
conrmation
Medical oncologist Sequence of therapies
Radiation oncologist EBRT and/or IORT
Urologist Cystoscopy, ureteral stenting, and/
or en bloc resections
Orthopedic surgeon and
En bloc resections
neurosurgeon
Plastic surgeon Reconstruction
Enterostomal therapist Stomal marking and training
Colorectal surgeon Coordination of overall care
EBR
T, External beam radiation therapy; IORT, intraoperative radiation
therapy.
o
f local structures, surgical specialists such as urologists, orthopedic surgeons, and/or neurosurgeons may be required to assist with
cystoscopy, ureteral stent placement, urologic organ resection and/
or reconstruction, and bone resection whenever sacral invasion is
suspected (Table 32-1).
Reoperative surgery in a previously irradiated eld is oen associated with poor wound healing. To diminish the likelihood of this
complication, plastic surgeons should assist in the reconstruction of
the perineum with myocutaneous aps. Patients should be evaluated preoperatively and undergo marking by enterostomal therapists
for sites of stoma placement (fecal and/or urinary). In addition, it is
important to ensure that medical comorbidities are optimally managed prior to surgery.
e surgical procedure should begin with an exploration
to exclude intraabdominal distant disease. If distant disease is
excluded, then dissection in the presacral space is pursued. Frozen
sections are helpful in dening margins of resection when distinguishing between brosis and malignancy is dicult. e lateral
planes are the most challenging because of the proximity of essential vascular structures. Ideally, all gross disease should be removed,
which may or may not require a wide en bloc resection. A key element in extensive surgical resection is to know when to stop because
leaving gross disease is unlikely to change the overall outcome in a
patient with an unresectable recurrence. Once the surgical removal
of the cancer is complete, proper mapping of the areas of concern
is performed in conjunction with the radiation oncology team to
target the best site for IORT (Box 32-1).
RECONSTR
UCTION OPTIONS FOR
PERINEAL DEFECTS
ealing of the perineal defect aer APR for recurrent rectal can-
H
cer may be prolonged and dicult, especially in patients who have
undergone preoperative CMT. In select patients, optimal healing
may be achieved with one of a variety of myocutaneous aps. ese
aps, based on a nonirradiated vascular pedicle, provide sucient
bulk to ll the dead space that follows a wide pelvic resection and signicantly lowers the perineal wound complication rate (16%) when
compared with primary closure of the perineum (44%).
X 32-1:
BO
•E
•A
•A
•Pur
•Usef
•K
•W
•W
hen performing surgery with the goal of a curative R0 resection for locally
* W
ecurrent rectal cancer, a sequence of decisions is necessary to facilitate the best
r
possible outcomes for the patient. During intraoperative exploration, if a curative
resection is deemed unlikely or becomes prohibitively dangerous, the colorectal
surgeon should recognize the need to stop because attempting a resection with the
potential for significant morbidity will either leave behind residual or gross disease
and/or is instantaneously life-threatening and would offer the patient no survival
benefit.
I
ORT, Intraoperative radiation therapy.
Operativ
xclude
traabdominalspread
in
ssessthepresacralspace
ssessthelateralplanes
sue
ide
aw
rozensections,asneeded
nowwhentostop
iththeIORTteam,maptheareaof
iththeplasticsurgeryteam,planreconstruction
e Decisions
locresection,asneeded
enb
*
co
ncern
Reconstruction options include gracilis (unilateral or bilateral),
gluteus muscle, and vertical rectus abdominis myocutaneous (VRAM)
aps. Advantages of the gracilis ap, based on the medial circumex
femoral branch of the profunda femoris artery, include proximity and
lack of donor-site morbidity. Disadvantages include a tenuous vascular
pedicle and oen insucient muscle bulk to ll a large pelvic defect. e
VRAM ap is similar to that used for breast reconstruction except that
it is based on the deep inferior epigastric vessels. Advantages include a
durable vascular pedicle, good muscle bulk, and ease of creation, resulting in minimal prolongation of operating time. When contemplating use
of a VRAM ap, careful preoperative planning is essential to ensure that
no prior surgery on the donor site would compromise blood supply to
the vascular pedicle and that the contralateral site is adequate for stoma
placement(s). In cases in which blood supply is an issue, a preoperative
CT angiogram of the chest and abdomen may help evaluate the vasculature of the VRAM and guide the choice of ap for reconstruction.
SUMMAR
e management of patients with recurrent rectal cancer requires
Y
careful preoperative evaluation of the patient and the recurrence. A
multidisciplinary team conference should be conducted to establish
an individualized strategy for treatment. Radical repeat resection for
carefully selected patients with pelvic recurrence oers excellent palliation, and in combination with CMT (including IORT), it results
in long-term survival in up to one third of patients. Improvements
in conventional imaging modalities including ERUS, MRI, CT, and
PET-CT may facilitate early diagnosis of local recurrence and accurate assessment of extent of local involvement, improving patient
selection and the likelihood of a curative resection.
g g e
u
S
A
Boyle KM, Sagar PM, Chalmers AG, etal. Surgery for locally recurrent rectal
Chessin DB, Hartley J, Cohen AM, etal. Rectus ap reconstruction decreases
Dozois EJ, Privitera A, Holubar SD, et al. High sacrectomy for locally re-
Dresen RC, Gosens MJ, Martijn H, etal. Radical resection aer IORT-con-
S t
lektiar KM, Zelefsky MJ, Paty PB, et al. High-dose-rate intraoperative
brachytherapy for recurrent colorectal cancer. Int J Radiat Oncol Biol Phys.
2000;48:219–226.
cancer. Dis Colon Rectum. 2005;48:929–937.
perineal wound complications aer pelvic chemoradiation and surgery: a
cohort study. Ann Surg Oncol. 2005;12:104–110.
current rectal cancer: can long-term survival be achieved? J Surg Oncol.
2011;103:105–109.
taining multimodality treatment is the most important determinant for
outcome in patients treated for locally recurrent rectal cancer. Ann Surg
Oncol. 2008;15:1937–1947.
e d
R
e
a d i n g
Соседние файлы в папке Библиотека им академика М.И. Перельмана
